Active Stocks
Thu May 23 2024 15:59:05
  1. Tata Steel share price
  2. 175.45 1.24%
  1. NTPC share price
  2. 372.30 -0.43%
  1. Power Grid Corporation Of India share price
  2. 319.75 -1.86%
  1. Indusind Bank share price
  2. 1,442.00 2.29%
  1. State Bank Of India share price
  2. 832.35 1.59%
Business News/ News / India/  Coronavirus vaccine update: Bharat Biotech to manufacture vaccine in Odisha
BackBack

Coronavirus vaccine update: Bharat Biotech to manufacture vaccine in Odisha

The Hyderabad-based BBIL is going to manufacture 10 types of vaccines, including malaria and the novel coronavirus
  • The total investment would be around ₹300 cr, the BBIL chief said
  • BBIL is a multi-dimensional biotechnology organisation specializing in manufacture of vaccines and bio-therapeutics. (MINT_PRINT)Premium
    BBIL is a multi-dimensional biotechnology organisation specializing in manufacture of vaccines and bio-therapeutics. (MINT_PRINT)

    In a good news for millions of Indians, Hyderabad-based Bharat Biotech International Ltd or BBIL announced that it is going to manufacture 10 types of vaccines, including malaria and the novel coronavirus, in its upcoming unit in Odisha.

    Attending a virtual meeting with state chief secretary Asit Tripathy on Friday, BBIL Chairman and Managing Director Dr. Krishna Ella said, "The company has taken up the development and production of new or improved vaccines against severe Rotavirus Diarrhoea, Malaria, Japanese Encephalitis, Rabies, Pandemic Influenza, and drug-resistant Staphylococcus aureus."

    Presenting BBIL's preparedness, Dr. Ella said that the best of technology will be put in the Odisha unit.

    Total investment to be around 300 cr

    "It's a unit at Andharua of Bhubaneswar which would produce ten types of vaccines including malaria and COVID-19 vaccine. The total investment would be around Rs. 300 crores and best of the technology will be put in the unit," Ella added.

    BBIL is a multi-dimensional biotechnology organisation specializing in manufacture of vaccines and bio-therapeutics, Ella said.

    Meanwhile, Asit Tripathy also assured the BBIL would be provided all support for future expansion of the unit at Andharua. He also directed the concerned authorities to start the ground level construction work within a fortnight and commence production within the scheduled time.

    Further, Tripathy asked BBIL to set up a 'state of art' biotech incubation center, common facilities, and IT corridor along with the first phase construction of the industry. The company was requested to promote local startups.

    Secretary Skill Development and Technical Education and Chairman and Managing Director IDCO Sanjay Kumar Singh appraised, "The land is readily available at Biotech Park, Andharua for groundbreaking works. The building plan as per the design has also been approved".

    Principal Secretary Santosh Sadangi said, "In the meanwhile, the required statutory clearances and pollution control board permission has been availed for setting up the unit".

    With agency inputs

    You are on Mint! India's #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 07 Nov 2020, 09:08 AM IST
    Next Story footLogo
    Recommended For You